Basic Information
Alunbrig
Regulatory Information
EMEA/H/C/004248
November 22, 2018
September 19, 2018
10
September 22, 2023
Company Information
Denmark
Delta Park 45 2665 Vallensbaek Strand
Takeda Pharma A/S
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non?small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.
Overview Summary
Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). It is used in patients who have not been treated before with a medicine of the ALK inhibitor class or who have been treated before with the ALK-inhibitor crizotinib. Alunbrig is only used if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). Alunbrig contains the active substance brigatinib.